Free tool
FAERS Monitor: Ridaura
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018689 or its brand name (Ridaura, Auranofin). Reports on generic versions are filed under their own applications.
Reports
205
Serious
156
76% of reports
Hospitalization
94
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity18
- drug ineffective16
- nausea15
- anaemia12
- fall11
- fatigue11
- pneumonia11
- pain10
- pyrexia9
- myocardial infarction8
- rheumatoid arthritis8
- abdominal pain upper7
- constipation7
- cough7
- dizziness7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 20 |
| 2005 | 21 |
| 2006 | 11 |
| 2007 | 8 |
| 2008 | 15 |
| 2009 | 14 |
| 2010 | 8 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 11 |
| 2014 | 9 |
| 2015 | 1 |
| 2016 | 10 |
| 2017 | 18 |
| 2018 | 22 |
| 2019 | 10 |
| 2020 | 4 |
| 2021 | 4 |
| 2023 | 1 |
| 2024 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,954 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 18 | 9.5 | 6.1 | 130 |
| rheumatoid arthritisSignal | 8 | 7.2 | 3.7 | 37 |
| anaemiaSignal | 12 | 6.5 | 3.7 | 50 |
| myocardial infarctionSignal | 8 | 4.7 | 2.4 | 20 |
| abdominal pain upperSignal | 7 | 3.5 | 1.7 | 10 |
| pneumoniaSignal | 11 | 3.5 | 2.0 | 17 |
| fallSignal | 11 | 3.4 | 1.9 | 16 |
| constipationSignal | 7 | 3.3 | 1.6 | 9 |
| pyrexiaSignal | 9 | 2.7 | 1.4 | 8 |
| coughSignal | 7 | 2.6 | 1.2 | 5 |
| nausea | 15 | 1.9 | 1.2 | 6 |
| pain | 10 | 1.7 | 0.9 | 2 |
| fatigue | 11 | 1.4 | 0.8 | 1 |
| dizziness | 7 | 1.4 | 0.7 | 1 |
| drug ineffective | 16 | 1.2 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.